OSCR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Oscar Health Inc. (OSCR) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has shown positive financial growth trends and has received some favorable analyst upgrades, the technical indicators and trading signals do not suggest a compelling entry point. Additionally, the stock's pre-market decline and lack of strong positive catalysts make it prudent to hold off on investing for now.
The MACD is positive but contracting, indicating weakening momentum. RSI is neutral at 79.634, and moving averages are converging, suggesting no clear trend. The stock is trading near its resistance level (R1: 16.821), with pre-market price at 16.29, down 0.85%.
Leadership change with the appointment of Siddhartha Sankaran as independent Chair of the Board, signaling potential strategic improvements.
Launch of the Lucie Health Marketplace, which could enhance market share and consumer engagement.
Revenue growth of 17.30% YoY in Q4 2025.
Pre-market price decline of 0.85%.
Net income remains negative at -$352.61M, despite improvement.
No significant insider or hedge fund trading trends, indicating neutral sentiment.
In Q4 2025, revenue increased by 17.30% YoY to $2.81B. Net income improved by 129.64% YoY but remains negative at -$352.61M. EPS improved by 100% YoY to -1.24. Gross margin remained at 0%.
Recent upgrades include Jefferies upgrading to Hold with a price target of $16 and Raymond James upgrading to Outperform with a price target of $18. UBS lowered its price target to $15 but maintained a Neutral rating. Analysts see potential in market share growth and margin recovery but remain cautious overall.
